Tech Company Financing Transactions
Hua Medicine Funding Round
Hua Medicine closed a $50 million Series C financing round on 4/26/2016. Backers included Harvest Investments, Ally Bridge Group and Fidelity Management & Research Company.
Transaction Overview
Company Name
Announced On
4/26/2016
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds complete long-term Phase 2 clinical trials this year, accelerate the Phase 3 development plans of HMS5552, a new 4th-generation glucokinase activator (GKA) for Type 2 diabetes, as well as advancing additional novel assets in its pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
275 Ai Di Sheng Road Zhangjiang Hi-Tech Park
Pudong Shanghai, 201203
China
Pudong Shanghai, 201203
China
Phone
Website
Email Address
Overview
Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Li Chen
Chief Financial Officer
George Lin
Vice President
Jin She
Vice President
Fu Yilei
VP - R & D
Yi Zhang
VP - Regulatory Affairs
Daniel Du
Browse more venture capital transactions:
Prev: 4/26/2016: HealthVerity venture capital transaction
Next: 4/26/2016: SparkCognition venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs